Holen Sie sich die Stockscreener-App
1.99
5.82%
0.11
Schlusskurs vom Vortag:
$1.88
Offen:
$1.88
24-Stunden-Volumen:
1.00M
Relative Volume:
0.63
Marktkapitalisierung:
$192.86M
Einnahmen:
$20.76M
Nettoeinkommen (Verlust:
$-132.49M
KGV:
-0.7453
EPS:
-2.67
Netto-Cashflow:
$-108.55M
1W Leistung:
-7.04%
1M Leistung:
+3.08%
6M Leistung:
-6.16%
1J Leistung:
-40.79%
1-Tages-Spanne:
$1.88
$2.035
1-Wochen-Bereich:
$1.83
$2.14
52-Wochen-Spanne:
$1.085
$3.72
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Firmenname
C 4 Therapeutics Inc
Sektor
Branche
Telefon
(617) 231-0700
Adresse
490 ARSENAL WAY, WATERTOWN
Vergleichen Sie CCCC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
1.99 | 182.20M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.23 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.23 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
847.29 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
350.76 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
345.36 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Eingeleitet | TD Cowen | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-15 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Equal-Weight |
| 2024-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-04-28 | Eingeleitet | Credit Suisse | Underperform |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-10 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-11-23 | Eingeleitet | BofA Securities | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-27 | Eingeleitet | Jefferies | Buy |
Alle ansehen
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics, Inc. (CCCC): A Bull Case Theory - Finviz
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 28, 2026 - BioSpace
C4 Therapeutics announces inducement grant under Nasdaq Listing Rule - marketscreener.com
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New C4 Therapeutics hire granted options on 85,480 shares - Stock Titan
Volume Report: Is FAMI a good ESG investmentQuarterly Profit Review & Smart Money Movement Alerts - baoquankhu1.vn
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
FY2028 EPS Forecast for C4 Therapeutics Reduced by Analyst - MarketBeat
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock By Investing.com - Investing.com Australia
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock - Investing.com
Insider Sell: Leonard Reyno Sells Shares of C4 Therapeutics Inc (CCCC) - GuruFocus
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Leonard Reyno Sells 10,000 Shares of C4 Therapeutics (NASDAQ:CCCC) Stock - MarketBeat
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Aug Intraday: Is Coincheck Group NV stock good for income investorsJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors - TipRanks
C4 Therapeutics to advance cemsidomide trials for multiple myeloma By Investing.com - Investing.com Nigeria
C4 Therapeutics (CCCC) Announces Ambitious Milestones Through 20 - GuruFocus
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways - Investing News Network
C4 Therapeutics to advance cemsidomide trials for multiple myeloma - Investing.com
C4 Therapeutics Outlines Strategic Milestones for Cemsidomide - TradingView
C4 Therapeutics Advances Cemsidomide Trials and Internal Discovery Strategy Ahead of Key Milestones Through 2028 - Quiver Quantitative
Potential multiple myeloma drug from C4 Therapeutics plans trials to 2028 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch - TipRanks
How C4 Therapeutics Inc. stock performs in weak economy - Улправда
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Is C4 Therapeutics Inc. stock trading at a premium valuationWeekly Trend Recap & Smart Swing Trading Techniques - Улправда
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Is C4 Therapeutics Inc. stock in correction or buying zoneJuly 2025 Big Picture & Safe Swing Trade Setups - Улправда
Finanzdaten der C 4 Therapeutics Inc-Aktie (CCCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):